SAN DIEGO--(BUSINESS WIRE)--KFx announced today the completion of the sale of AppianFx, a unique soft tissue fixation system, to Conmed Corporation. The transaction consideration was not disclosed.
“The AppianFx system fits perfectly within the broad Sports Medicine Conmed product line,” remarked Tate Scott, president and CEO of KFx, LLC. “We are pleased to see this remarkable product get the broader exposure possible from the Conmed sales force. Their sales force is already in the procedures in which the AppianFx is used so this should experience great further exposure.”
In a separate matter, on November 17, 2015, KFx Medical announced that a petition for writ of certiorari filed by Arthrex was denied by the Supreme Court of the United States. The Supreme Court refused Arthrex’s request for review of a patent infringement judgment in favor of KFx Medical. Arthrex has paid in excess of $35m in damages and interest for its infringement of KFx’s Knotless Double Row Fixation method as described in KFx’s U.S. Patent No. 7,585,311.
Headquartered in Solana Beach, Calif., KFx Medical was founded in 2003 to develop products for tissue fixation in a variety of orthopedic surgical procedures performed on the shoulder, knee, foot, and ankle.
The company is privately held — Investors include Alloy Ventures, Charter Life Sciences, Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.
